Evofem Biosciences is a San Diego-based biopharmaceutical company developing women's sexual and reproductive health products. The company focuses on products for women's sexual and reproductive health. In 2019 it announced additional financing from PDL BioPharma. PDL provided $30M in April and a further $50M in June as part of an $80M financing package. The announcement indicates the company is actively securing capital to support its development efforts. No operating metrics or other financial details beyond the disclosed financing amounts are reported in the article. Evofem is a San Diego-based biotechnology firm focused on developing new contraceptives for the women's reproductive health market. The company is led by Saundra Pelletier. In August 2016 Evofem announced a $25M Series D financing. The funding came from Woodford Investment Management. Proceeds are designated for clinical and commercialization infrastructure and to support its current technology pipeline. The raise is intended to advance clinical work and build commercialization capabilities. EVOFEM, based in La Jolla, San Diego, CA, markets feminine hygiene products and is developing technologies in women’s reproductive health. Its lead drug candidate, Amphora, is being evaluated as a microbicide to protect women from pregnancy and sexually transmitted diseases, including HIV/AIDS. The company plans to use the new proceeds to accelerate commercialization of Amphora and to advance a program with Médecins Sans Frontières to distribute the product in Africa. Management highlighted the potential impact of the technology on the AIDS pandemic worldwide. The company also added Dr. Kenneth Herbst, former Deputy Surgeon General of the Army for Reserve Affairs and a UCSD professor of medicine, to its medical advisory board.

Total raised

$100M

Funding rounds

3

Latest round

Equity

Latest activity

Jun 2019